Form 4: Invivyd Director Marc Elia Awarded Stock Option

Marc Elia, a director of Invivyd, Inc., was granted a stock option for 50,000 shares on May 20, 2025, as reported in a Form 4 filing.

Summary

• A Form 4 filing reveals that Marc Elia, a director of Invivyd, Inc., received a stock option to purchase 50,000 shares of common stock.
• The option was granted on May 20, 2025, with an exercise price of $0.8092 per share.
• The option vests on the earlier of May 20, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continuous service.
• M28 Capital Management LP, which Marc Elia indirectly controls, may be deemed a director by deputization.
• Both Marc Elia and M28 Capital Management LP have filed the report, disclaiming beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock option grant, which is neither particularly positive nor negative on its own.

Positives

• The granting of stock options to directors can align their interests with those of shareholders, potentially incentivizing value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock option.

Management Comments

• The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This grant is typical for directors of publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their director compensation plans.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that benefit shareholders, but the direct impact is likely minimal.

Key Dates

Keywords

Form 4, Invivyd, Stock Option, Director, Marc Elia, M28 Capital Management, Beneficial Ownership, Equity Securities